Enduring Efficacy and Tolerability of Daratumumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma ( GEN 503): Final Results of an Open‐label, Phase 1/2 Study
British Journal of Haematology - United Kingdom
doi 10.1111/bjh.15879
Full Text
Open PDFAbstract
Available in full text
Categories
Date
March 31, 2019
Authors
Publisher
Wiley